Stockscreener 앱 받기
5.65
2.17%
0.12
시간 외 거래:
5.61
-0.04
-0.71%
전일 마감가:
$5.53
열려 있는:
$5.545
하루 거래량:
659.88K
Relative Volume:
0.43
시가총액:
$267.49M
수익:
-
순이익/손실:
$-8.21M
주가수익비율:
-32.56
EPS:
-0.1735
순현금흐름:
$-3.31M
1주 성능:
+21.51%
1개월 성능:
+111.61%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.45
$5.85
1주일 범위
$4.34
$7.48
52주 변동 폭
$2.201
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
5.65 | 261.81M | 0 | -8.21M | -3.31M | -0.1735 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 개시 | Maxim Group | Buy |
Polaryx Therapeutics Inc 주식(PLYX)의 최신 뉴스
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
PLYX: Polaryx Therapeutics, Inc.Comparative Chart - Zacks Investment Research
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa
Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - TipRanks
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com
Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times
FDA Fast Track for PLX‑200 targeting rare pediatric disorder - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Polaryx Therapeutics Stock Rises Amidst Key Clinical Trials Development - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics Stock Surges With New Phase Trial Decision - StocksToTrade
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget
Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? - Asianet Newsable
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
PLYX Forecast, Price Target & Analyst Ratings | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
PLYX | Polaryx Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ - EIN News
Polaryx Therapeutics (PLYX) 10K Form and SEC Filings 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Price, News & Analysis - MarketBeat
Polaryx Therapeutics (PLYX) Stock Chart and Price History 2026 - MarketBeat
Insider Buying: G. Landis Acquires Shares of Polaryx Therapeutics Inc (PLYX) - GuruFocus
PLYX Stock Price, News & Analysis - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
What's Going On With Polaryx Therapeutics Stock Wednesday? - Benzinga
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Polaryx selects CRO for phase 2 trial of rare disease treatment - Investing.com South Africa
What is the current Price Target and Forecast for Polaryx Therapeutics, Inc. (PLYX) - Zacks Investment Research
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans - Bitget
SMJ INTERNATIONAL HOLDINGS INC. (SMJF) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics Surges Amid Strategic Market Moves - StocksToTrade
Polaryx Therapeutics Sees Strategic Moves Amid Market Volatility - timothysykes.com
Polaryx selects CRO for Soteria Phase 2 trial - TipRanks
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx Therapeutics selects contract research organization for Soteria phase 2 basket trial - marketscreener.com
Rare-disease biotech readies Phase 2 trial across four childhood disorders - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Polaryx Therapeutics Inc (PLYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):